Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

Journal of Hematology and Oncology

Volumn 4, Issue , 2011, Pages

  Kim, Yu Ri ^a   Kim, Jin Seok ^a   Kim, Soo Jeong ^a   Jung, Hyun Ae ^b   Kim, Seok Jin ^b   Kim, Won Seog ^b   Lee, Hye Won ^c   Eom, Hyeon Seok ^c   Jeong, Seong Hyun ^d   Park, Joon Seong ^d   Cheong, June Won ^a   Min, Yoo Hong ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c National Cancer Center   (South Korea)

^d Ajou University School of Medicine   (South Korea)

Author keywords

international prognostic index; lymphopenia; not otherwise specified; peripheral T cell lymphoma; prognostic factor

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ABSOLUTE LYMPHOCYTE COUNT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PROGRESSION FREE SURVIVAL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; DISEASE FREE SURVIVAL; MIDDLE AGED; PROGNOSIS; SOUTH KOREA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOMA, T-CELL, PERIPHERAL; LYMPHOPENIA; MALE; MIDDLE AGED; PROGNOSIS; REPUBLIC OF KOREA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051580303     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-4-34     Document Type: Article

References (29)

1. Peripheral T-cell lymphomas. Savage KJ, Blood reviews 2007 21 201 216 10.1016/j.blre.2007.03.001 17512649 (Pubitemid 46880004)
2. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. Vose J, Armitage J, Weisenburger D, Journal of clinical oncology 2008 26 4124 4130 18626005
3. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. Agostinelli C, Piccaluga PP, Went P, Rossi M, Gazzola A, Righi S, Sista T, Campidelli C, Zinzani PL, Falini B, Pileri SA, Journal of Clinical Pathology 2008 61 1160 1167 10.1136/jcp.2008.055335 18755717
4. T-cell non-Hodgkin lymphoma. Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST, Blood 2006 107 1255 1264 10.1182/blood-2005-03-1306 16210342 (Pubitemid 43242357)
5. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Escaln MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL, Dang NH, Cancer 2005 103 2091 2098 10.1002/cncr.20999 15816054 (Pubitemid 40605117)
6. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, et al. Blood 2004 103 2474 2479 10.1182/blood-2003-09-3080 14645001 (Pubitemid 38392996)
7. Comparison of four prognostic scores in peripheral T-cell lymphoma. Gutirrez-Garca G, Garca-Herrera A, Cardesa T, Martnez A, Villamor N, Ghita G, Martnez-Trillos A, Colomo L, Setoain X, Rodrguez S, et al. Annals of oncology 2011 22 397 404 10.1093/annonc/mdq359 20631009
8. International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: Poor Outcome by Prognostic Indices and Lack of Efficacy with Anthracyclines. Vose JM, Blood 2005 106 811a
9. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. The New England journal of medicine 1993 329 987 994 8141877
10. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Martinez Delgado B, Melndez B, Cuadros M, Alvarez J, Castrillo JM, Ruiz De La Parte A, Mollejo M, Bellas C, Diaz R, Lombarda L, et al. Clinical cancer research 2004 10 4971 4982 10.1158/1078-0432.CCR-04-0269 15297397 (Pubitemid 39099770)
11. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Martnez-Delgado B, Cuadros M, Honrado E, Ruiz de la Parte A, Roncador G, Alves J, Castrillo JM, Rivas C, Bentez J, Leukemia 2005 19 2254 2263 10.1038/sj.leu.2403960 16270046 (Pubitemid 41741622)
12. Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Rodrguez-Antona C, Leskel S, Zajac M, Cuadros M, Alvs J, Moneo MV, Martn C, Cigudosa JC, Carnero A, Robledo M, et al. Blood 2007 110 3345 3351 10.1182/blood-2007-02-075036 17634410 (Pubitemid 350106328)
13. Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. Cox MC, Nofroni I, Laverde G, Ferrari A, Amodeo R, Tatarelli C, Saltarelli F, Veggia B, Aloe-Spiriti MA, Ruco L, Monarca B, British journal of haematology 2008 141 265 268 10.1111/j.1365-2141.2008.07028.x 18353165 (Pubitemid 351406210)
14. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, Cardelli P, Montefusco E, Conte E, Monarca B, Aloe-Spiriti MA, Leukemia & lymphoma 2008 49 1745 1751 10.1080/10428190802226425 21845476
15. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, Morishima Y, European journal of haematology 2008 81 448 453 10.1111/j.1600-0609.2008. 01129.x 18691256
16. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, Song HS, Chung JS, Hyun MS, Sohn SK, Leukemia 2007 21 2227 2230 10.1038/sj.leu.2404780 17554383 (Pubitemid 47423827)
17. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Behl D, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, et al. British journal of haematology 2007 137 409 415 10.1111/j.1365-2141.2007.06596.x 17433025 (Pubitemid 46698290)
18. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, et al. Cancer research 2009 69 5383 5391 10.1158/0008-5472.CAN-08-3845 19549917
19. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. Hasenclever D, Diehl V, The New England journal of medicine 1998 339 1506 1514 10.1056/ NEJM199811193392104 9819449 (Pubitemid 28543499)
20. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Porrata LF, Rsitow K, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Colgan JP, Nowakowski GS, et al. Leukemia 2010 24 1343 1349 10.1038/leu.2010.108 20485372
21. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN, American journal of hematology 2009 84 93 97 10.1002/ajh.21337 19123458
22. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Huang JJ, Jiang WQ, Lin TY, Huang Y, Xu RH, Huang HQ, Li ZM, Annals of oncology 2011 22 149 155 20595450
23. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lpez A, Hagenbeek A, et al. Journal of clinical oncology 1999 17 1244 1244 10561185
24. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Weisenburger D, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, Maclennan KA, Rdiger T, Pileri S, Nakamura S, Nathwani B, et al. Blood 2011 117 3402 3408 10.1182/blood-2010-09- 310342 21270441
25. Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Castillo J, Morales D, Quinones P, Cotrina E, Desposorio C, Beltran B, Leukemia & lymphoma 2010 51 1822 1828 10.3109/10428194.2010. 508189 21845476
26. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, Clarke SJ, Clinical cancer research 2010 16 5805 5813 10.1158/1078-0432.CCR-10-2245 20956618
27. Cellular and molecular pathways linking inflammation and cancer. Porta C, Larghi P, Rimoldi M, Totaro MG, Allavena P, Mantovani A, Sica A, Immunobiology 2009 214 761 777 10.1016/j.imbio.2009.06.014 19616341
28. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, et al. Annals of oncology 2007 18 1209 1215 10.1093/annonc/mdm110 17496307 (Pubitemid 47244368)
29. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Borg C, Ray Coquard I, Philip I, Clapisson G, Bendriss Vermare N, Menetrier Caux C, Sebban C, Biron P, Blay J, Cancer 2004 101 2675 2680 10.1002/cncr.20688 15503313 (Pubitemid 39532301)